DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Pignata S, Lorusso D, Joly F. et al.
Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.
J Clin Oncol 2018;
36: 5506
Access:
We do not assume any responsibility for the contents of the web pages of other providers.